Lupin receives tentative approval from USFDA for its HIV drug

24 Jul 2023 , 11:53 AM

For its new medicine application for tablets containing dolutegravir lamivudine and tenofovir alafenamide, Lupin has got provisional approval from the US Food and Drug Administration (US FDA) under PEPFAR.

This item would be produced at the business’ Indian factory in Nagpur.

Hormosan Pharma GmbH (Hormosan), the company’s wholly-owned subsidiary in Germany, introduced Luforbec 100/6 on July 21. This fixed combination in a pressurized metered dose inhaler (pMDI) is intended to treat adult asthma and chronic obstructive pulmonary disease (COPD).

Additionally, the corporation established a fully owned subsidiary, Lupin Atharv Ability Limited, for the neuro-rehabilitation industry.

On August 3, 2023, the company’s board of directors will meet to discuss and record the unaudited financial results for the quarter that ended on June 30, 2023.

As of 9:40 am, Lupin’s share price was up 0.6% at Rs 940.60 after the company acquired provisional approval from the USFDA for its HIV medication.

For feedback and suggestions, write to us at [e-mail]